News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
Jaguar Health, Inc. announces virtual presentation by CEO Lisa Conte at Life Sciences Virtual Investor Forum on June 24, 2026. Crofelemer presentations at ESPGHAN Meeting -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Jaguar Health's crofelemer, an FDA-approved botanical drug derived from Croton lechleri tree, developed as first oral adjunctive therapy for Intestinal Failure (IF) from MVID and SBS, highlighting unique botanical drug platform and indigenous collaboration -
